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OBJECTIVE: To compare subjective response and com-
pliance of olanzapine-treated patients and patients treated
with other antipsychotics in an observational prospective
study (EFESO). METHODS: Outpatients entered the
study when they received a new prescription of an antip-
sychotic drug. Patients treated with olanzapine (n 
2128), risperidone (n  417) and haloperidol (n  112)
were included in the analysis. Subjective response was
measured using the 10-item version of the Drug Attitude
Inventory (DAI-10). Treatment compliance was mea-
sured using a physician-rated 4 point categorical scale.
Subjective response and compliance were compared be-
tween the treatment groups. Data were collected at base-
line and after 3 and 6 months. RESULTS: Overall mean
doses were respectively 13 mg, 5.4 mg and 13.6 mg for
olanzapine, risperidone and haloperidol treated patients.
All three groups had a positive subjective response to
treatment. Olanzapine treated patients had significantly
higher DAI-10 score compared to both risperidone and
haloperidol treated patients at 3 months (P  0.003 and
P  0.001 respectively) and at 6 months (P  0.001 vs
risperidone and haloperidol). Risperidone-treated patients
had a higher DAI-10 score compared to haloperidol-
treated patients at both 3 months and 6 months (P  0.003).
Olanzapine-treated patients had significantly better treat-
ment compliance compared to both risperidone and halo-
peridol treated patients at 6 months (P  0.001 and P 
0.022 respectively). CONCLUSION: Despite the limita-
tions of an observational study, these results suggest that
in routine clinical practice, olanzapine-treated patients
exhibit a superior subjective response and compliance
compared to risperidone and haloperidol treated patients.
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OBJECTIVE: A model was developed to assess the clinical
outcome and costs of an intensive deinstitutionalization
strategy called Intensive Case Management (ICM) in com-
parison to Standard Case Management (SCM) for persons
suffering of chronic schizophrenia and long term hospital-
ized (1 year). METHODS: A Markov Model was con-
structed to describe the different possibilities of case man-
agement of long term hospitalized schizophrenic patients.
The Markov states were classified to one of five categories
hospital, institution, outpatient, dropout, and death, fol-
lowed by either success or failure of the adopted case man-
agement. Clinical, functioning improvement, and patient
discharge from acute care unit define success here. The
Markov process iterates in 1-year cycles until the 5-year.
Model probabilities are gathered from an ongoing ambi-
spective cohort of patients assigned to ICM or SCM in the
catchment area of Clermont-Ferrand. Control patients
(SCM) were/are retrospectively chosen on the premise that
they could have been selected for ICM group. Service utili-
zation data are obtained from patient medical and adminis-
trative record while direct costs are obtained from the ana-
lytical accounting system of the catchment area. RESULTS:
Based on the primary data collected (ICM: n  42, SCM:
n  28), the outcomes of the two types of care showed,
that the ICM was more effective in terms of success over
the first one-year period 59% of the patients experienced a
success as opposed to 25% in SCM. It was also shown that
readmission to hospital was more likely in the SCM (67%
as opposed to 22% in ICM). A threshold analysis will be
performed in order to evaluate at which point ICM will
be too costly for the hospital budget. CONCLUSIONS:
With these outcome results, ICM is shown to be more ef-
fective than SCM. The model will be used to generate cost-
effectiveness ratios, budgetary previsions for large-scale im-
plementation of ICM, in order to help decision-makers in
policy-making for mental health care organizations.
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OBJECTIVE: To assess the concordance of self reports,
parental reports and urine drug bioassays as measures of
drug use in adolescents treated for chemical dependency.
Questions addressed are, (1) what is the concordance be-
tween self reports, parental reports and bioassays? (2)
does the concordance vary over time? METHODS: Anal-
yses are based on panel study data from 119 adolescents
and their parents. Each adolescent completed drug treat-
ment at the same facility in the same time period. To as-
sess treatment effectiveness adolescents and their parents
were followed prospectively and interviewed separately
with a standardized questionnaire at 3, 6, 9 and 12 months
post treatment. Random urine bioassays via enzyme im-
munoassay were administered during the study. Each ad-
olescent was drug tested a minimum of 9 times. RESULTS:
Eighty-one percent of the adolescents self-reported sub-
stance use during the study period and 31% had a posi-
tive urine bioassays (Cohen’s Kappa 	  .077, P  .388).
Sixty-five percent reported using alcohol while there were
no bioassays positive for alcohol. The concordance be-
tween reported marijuana use and positive urine bioas-
says showed that 48% reported using marijuana while
29% had a positive marijuana bioassay (	  .40, P 
.006). Fifty-two percent reported using several different
substances but had as many as ten negative drug screens.
Sixty four percent of the parents of the adolescents who
reported use confirmed that their child used in the first
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three months (	  .42, P  .001). Scores for the 6, 9 and
12-month survey were (	  .451, P  .001; 	  .755, P 
.001 and 	  .183, P  .074), respectively. No signifi-
cant concordances between parental reports and bioas-
says were noted in any of the time intervals. CONCLU-
SION: This research shows a strong degree of concordance
between adolescent and parental reports of drug and al-
cohol use. It shows that there is a lesser degree of concor-
dance between both adolescent and parental reports and
urine bioassays. When evaluating the results of this re-
search one must realize that the adolescents knew they
were would be required to give urine specimens and they
also knew that their parents would be contacted to cor-
roborate their responses. It is possible that such knowl-
edge may yield more valid reporting. These findings sug-
gest that outcomes data is best collected by querying
adolescents and their parents while subjecting the adoles-
cents to random drug urine bioassays. It also suggests
that the urine bioassays are far from being a gold stan-
dard. Considering the high cost of urine bioassays, less
frequent screens may be warranted if their primary effect
is that of increasing the reliability of reports. Measuring
the outcomes of substance abuse treatment services
hinges on researcher’s ability to measure post treatment
drug and alcohol use. Since alcohol and drug use are ille-
gal and socially stigmatized behaviors accurately measur-
ing their prevalence is difficult. This research suggests
that outcome measurement data should be triangulated—
that is, several different methods of data collection
should be used to assess drug and alcohol use—giving
first preference to the self reports of the adolescents, and
then using parental reports when the adolescent is unable
or unwilling to participate and using infrequent but ran-
dom urine bioassays to increase the reliability of the self-
reports.
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OBJECTIVE: to assess medical costs of dementia for pa-
tient (P) and health system (HS) and identify determi-
nants of high costs. METHODS: Study population 
605 subjects  65 years: two referent cohorts of 106 sub-
jects without cognitive impairment and 113 subjects with
cognitive impairment but no dementia and one cohort of
386 patients with mild (MMSE  21, n  83), moderate/
mild (MMSE 15–20, n  108), moderate (MMSE 10–14,
n  62) or severe (MMSE  10, n  133) dementia.
Medical costs were calculated using retrospective data
covering the last 12 months and included visits from GPs
and to specialists, physiotherapy, nursing, hospitaliza-
tions, medications, material for incontinence. For de-
mented patients, costs were calculated according to place
of living (community, n  218; institution, n  168). To-
tal costs and costs for HS and P were expressed as mean
monthly costs. Multivariate covariance analysis was used
to test the effect of dementia on medical costs controlling
for other cost determinants. RESULTS: Total costs: the
highest costs were for demented patients in institution,
with an increase according to severity (17,077, 45,433,
44,082 and 61,667 Bef in the four subcohorts). The main
cost components were nursing and hospitalizations. Costs
for P: the highest costs were incurred for severely de-
mented patients at home or in institution (5464 and 4191
Bef respectively), the main component being medications.
Costs for HS: the highest costs were for demented pa-
tients in institution: 57,476 Bef for severe, 41,525 and
40,769 Bef for moderate/mild and moderate, 13,541 Bef
for mild cases. By comparison costs for severely de-
mented at home amounted to 14,165 Bef. In covariance
analysis, dementia increased medical costs by 44% in
comparison to referent subjects (95% CI: 18%–75%) af-
ter adjusting for age, VIPO status and co-morbidity. The
increase was proportional to severity. Results of prospec-
tive data collection will be presented; implications will be
discussed.
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OBJECTIVES: This analysis was conducted to examine
the principal cost drivers for patient care within the Na-
tional Outcomes Measurement Study in Schizophrenia, a
longitudinal, observational study of the clinical, human-
istic, and economic outcomes of Canadian schizophrenia
patients. METHODS: To date, 376 patients have been
recruited from 32 academic and community sites across
Canada. Inpatient (hospitalizations) and outpatient (health
professional visits, counseling, legal costs, employment
status) resource use (RU) is collected monthly from all
patients. Physician-reported RU includes psychiatric medi-
cations. Mean costs of care per patient-month were estab-
lished during the first three months after registration, and
regression models measured the predictive power of base-
line demographic and clinical parameters. RESULTS: At
registration, 67% of the study patients were male, 90%
Caucasian, 41  11 years with an average age of onset of
psychotic symptoms of 23  7 years and an average du-
ration of symptoms of 17  11 years. Seventy percent
had a Clinical Global Impression score of “mild to mod-
erately ill”; 72% had a CGImprovement score of at least
“minimally improved” and the mean SOFAS score was
60  13. Based on 364 patients with at least 2 m of RU
data, the average total cost was $CDN 3441 per patient-
month, ($772: pharmaceuticals, $1430: inpatient care,
